Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Antibodies, Monoclonal / economics Antineoplastic Agents / economics Carcinoma, Non-Small-Cell Lung / drug therapy Cost-Benefit Analysis Humans Lung Neoplasms / drug therapy Quality-Adjusted Life Years

Journal

PharmacoEconomics
ISSN: 1179-2027
Titre abrégé: Pharmacoeconomics
Pays: New Zealand
ID NLM: 9212404

Informations de publication

Date de publication:
04 2020
Historique:
pubmed: 10 12 2019
medline: 23 3 2021
entrez: 10 12 2019
Statut: ppublish

Résumé

As part of the Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (AstraZeneca) of durvalumab (IMFINZI

Identifiants

DOI: 10.1007/s40273-019-00870-w PMID: 31814080 PMC: PMC7080309
pubmed: 31814080
doi: 10.1007/s40273-019-00870-w
pii: 10.1007/s40273-019-00870-w
pmc: PMC7080309
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antineoplastic Agents 0
durvalumab 28X28X9OKV

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Pagination

317-324

Subventions

Organisme : Department of Health
Pays : United Kingdom

Références

N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21
pubmed: 28881918
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881

Auteurs

Willem J A Witlox (WJA)

Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), PO Box 5800, 6202 AZ, Maastricht, The Netherlands. willem.witlox@mumc.nl.
ORCID: 0000-0003-1007-4284

Antoinette D I van Asselt (ADI)

Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), PO Box 5800, 6202 AZ, Maastricht, The Netherlands.
Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Robert Wolff (R)

Kleijnen Systematic Reviews Ltd, York, UK.

Nigel Armstrong (N)

Kleijnen Systematic Reviews Ltd, York, UK.

Gill Worthy (G)

Kleijnen Systematic Reviews Ltd, York, UK.

Annette Chalker (A)

Kleijnen Systematic Reviews Ltd, York, UK.

Titas Buksnys (T)

Kleijnen Systematic Reviews Ltd, York, UK.

Lisa Stirk (L)

Kleijnen Systematic Reviews Ltd, York, UK.

Jos Kleijnen (J)

Kleijnen Systematic Reviews Ltd, York, UK.
Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.

Manuela A Joore (MA)

Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), PO Box 5800, 6202 AZ, Maastricht, The Netherlands.
Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.

Sabine E Grimm (SE)

Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), PO Box 5800, 6202 AZ, Maastricht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Durvalumab for the Treatment of Locally...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Durvalumab for the Treatment of Locally...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Tumeurs des bronches › Carcinome bronchogénique › Carcinome pulmonaire non à petites cellules › Durvalumab for the Treatment of Locally...
questionsmedicales.fr › Organisations et économie des soins de santé › Économie › Coûts et analyse des coûts › Analyse coût-bénéfice › Durvalumab for the Treatment of Locally...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Durvalumab for the Treatment of Locally...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Durvalumab for the Treatment of Locally...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Espérance de vie › Années de vie ajustées sur la qualité › Durvalumab for the Treatment of Locally...